UK Regulators Investigate Peptide Clinic Medical Claims

The UK’s medicines regulator has opened an investigation into clinics offering peptide-based treatments , after a rise in the unregulated use of these substances alongside therapeutic marketing. Officials said the inquiry is driven by concerns about safety and effectiveness where peptides are promoted for outcomes such as injury repair, weight loss, and anti-aging.

The Medicines and Healthcare products Regulatory Agency (MHRA) said it is examining whether products supplied or promoted by these clinics are being presented with medicinal claims. If they are, the MHRA indicated they may fall under the Human Medicines Regulations 2012, which would mean the products require a marketing authorization to be legally sold or supplied in the UK.

Peptides are short chains of amino acids. Some occur naturally in the body, with insulin cited as an example, while others are manufactured. The MHRA’s focus is not on peptides as a category, but on how certain peptide products are being marketed and used, particularly where claims are made without robust scientific validation in human trials.

Officials noted that some approved prescription medicines use synthetic peptides, including semaglutide (Wegovy) and tirzepatide (Mounjaro). At the same time, the agency highlighted that a substantial part of the broader market involves experimental peptides sold for self-injection without regulatory oversight, creating a gap between regulated medicines and products promoted outside established authorization pathways.

The MHRA said unregulated peptide use has gained visibility among athletes and influencers. Officials added that promotional claims in this area are often rooted in animal or cellular studies rather than validated evidence from human clinical trials, raising questions about both efficacy and potential harm when products are used in people.

Two examples cited were BPC-157 and TB-500, which are marketed for injury recovery. Officials said these substances show promise in animal studies but do not have validated human trial data, and they noted that TB-500 is a banned substance in sports.

The regulator also warned that labeling products “for research purposes only” does not automatically place them outside enforcement. The MHRA said such wording does not prevent scrutiny if promotional materials indicate an intention for human use.

Officials said the agency is prepared to take action to ensure compliance with medicines rules, including removing products. The investigation, the MHRA said, reflects a wider public health concern about the spread of unproven medical treatments and the need for stronger enforcement as the peptide market expands.